Formycon’s Lucentis Biosimilar Enters Swiss and Canada Markets

The Firm’s Ranibizumab Biosimilar FYB201 Is Already Available In 17 Countries

 
• By Urtė Fultinavičiūtė
  
National flags of Canada and Switzerland
• Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products